CTLA-4
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), also known as CD152, is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is a member of the immunoglobulin superfamily and is expressed on the surface of T cells. CTLA-4 is homologous to the T-cell co-stimulatory receptor CD28, but it delivers an inhibitory signal to T cells.
Structure[edit | edit source]
CTLA-4 is a type I transmembrane protein with a single extracellular immunoglobulin-like domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain binds to B7-1 (CD80) and B7-2 (CD86) on antigen-presenting cells (APCs), which are the same ligands for CD28. However, CTLA-4 binds these ligands with higher affinity than CD28, leading to competitive inhibition.
Function[edit | edit source]
CTLA-4 plays a critical role in maintaining immune homeostasis and preventing autoimmunity. When T cells are activated, CTLA-4 is upregulated and competes with CD28 for binding to B7 molecules on APCs. This interaction transmits an inhibitory signal to the T cell, reducing its proliferation and cytokine production. This mechanism is essential for the regulation of T cell responses and the prevention of autoimmune diseases.
Clinical Significance[edit | edit source]
CTLA-4 has been implicated in various autoimmune diseases, such as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis. Genetic polymorphisms in the CTLA-4 gene have been associated with susceptibility to these conditions. Additionally, CTLA-4 is a target for cancer immunotherapy. Ipilimumab, a monoclonal antibody that blocks CTLA-4, has been approved for the treatment of melanoma and is being investigated for other types of cancer. By inhibiting CTLA-4, ipilimumab enhances T cell activation and promotes anti-tumor immunity.
Research[edit | edit source]
Ongoing research is focused on understanding the precise mechanisms of CTLA-4-mediated inhibition and its role in various diseases. Studies are also exploring the potential of combining CTLA-4 blockade with other immunotherapies to improve clinical outcomes in cancer patients.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This immunology article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
